Home › Funds › DeepCurrents Investment Group LLC › VRDN
DeepCurrents Investment Group LLC position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
DeepCurrents Investment Group LLC reported holding 19,460,000 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$22.3M, representing 0.74% of its reported portfolio and ranking #47 among its reported holdings. DeepCurrents Investment Group LLC has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How DeepCurrents Investment Group LLC's VRDN position evolved
DeepCurrents Investment Group LLC first disclosed a stake in VRDN in Q2 2026 at 11,960,000 shares (US$12.8M). The position peaked in Q3 2026 at 19,460,000 shares, worth US$22.3M. Across 2 filings, DeepCurrents Investment Group LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 19,460,000 shares valued at US$22.3M — an increase of 7,500,000 shares quarter over quarter.. Notable position changes include a 63% increase in Q3 2026 (shares rose 50% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 11.96M | $12.78M | New |
| Q3 2026 | 19.46M | $22.26M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- Paradigm Biocapital Advisors LP 6.72M sh · $123.52M · Q2 2026
- Kynam Capital Management, LP 6.45M sh · $118.56M · Q2 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.59M sh · $66.00M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $59.85M · Q2 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $45.92M · Q2 2026
- BAKER BROS. ADVISORS LP 2.38M sh · $43.78M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M sh · $39.22M · Q2 2026
More on DeepCurrents Investment Group LLC
FAQ
How long has DeepCurrents Investment Group LLC held VRDN?
DeepCurrents Investment Group LLC has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is DeepCurrents Investment Group LLC's current position in VRDN?
As of Q3 2026, DeepCurrents Investment Group LLC holds 19.46M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $22.26M, representing 0.74% of its reported portfolio and ranking #47.
Has DeepCurrents Investment Group LLC been buying or selling VRDN?
In the latest 13F filing (Q3 2026), DeepCurrents Investment Group LLC increased its position in VRDN. The position peaked in Q3 2026 at 19.46M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.